Therapy Areas: Oncology
Innovent Biologics doses first patient in phase one IBI321 study
26 July 2021 -

Innovent Biologics Inc (HKEX: 01801), a biopharmaceutical company, announced on Sunday that it has dosed its first patient in a phase one study of IBI321, an anti-PD-1/TIGIT bispecific antibody.

The aim of this open-label, multi-centre Phase 1a dose escalation and expansion study is to assess the safety, tolerability, potential optimal dosage and preliminary efficacy of IBI321 in patients with advanced malignant tumours whose cancer progressed on standard-of-care treatment. The company is conducting the trial in China.

This product is a bispecific antibody that has the potential to improve efficacy by synergistically targeting both PD-1 and TIGIT.



Related Headlines